Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veldoreotide - Strongbridge Biopharma

Drug Profile

Veldoreotide - Strongbridge Biopharma

Alternative Names: COR-005; DG-3173; PTR-3173; Veldotide

Latest Information Update: 17 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peptor
  • Developer Strongbridge Biopharma
  • Class Antineoplastics; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Somatostatin receptor 2 agonists; Somatostatin receptor 5 agonists; Somatostatin receptor subtype 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly
  • No development reported Adrenal cortical hyperfunction; Diabetic retinopathy; Neuroendocrine tumours

Most Recent Events

  • 08 Aug 2018 Strongbridge Biopharma has patent protection for veldoreotide extended release formulation in USA
  • 08 Aug 2018 Preclinical trials in Acromegaly in USA (Controlled release) before August 2018
  • 14 Nov 2017 Strongbridge Biopharma files for patent protection for its PLGA microspheres-based proprietary long-acting formulation for veldoreotide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top